359 Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC)

Antonio Pousa, Enriqueta Felip, Martin Forster, Bernard Doger, Patricia Roxburgh, Pawan Bajaj, Julio Peguero, Enric Carcereny, Matthew Krebs, Christian Mueller, Frederic Triebel

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Pages (from-to)A386-A386
JournalJournal for ImmunoTherapy of Cancer
Publication statusPublished - 1 Nov 2021

Cite this